Vera Therapeutics (VERA) Interest Expenses (2020 - 2026)

Vera Therapeutics has reported Interest Expenses for 7 years, with the latest figure at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 1.73% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 0.67% YoY), and the FY2025 full-year result was $7.5 million, down 1.25% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.8 million, down from $1.9 million in the prior quarter.
• The five-year high for Interest Expenses was $2.0 million in Q3 2025, with the low at $118000.0 in Q1 2022.
• Historically, Interest Expenses has averaged $1.3 million across 5 years, with a median of $1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 2895.0% — and 2025, when it decreased 5.98%.
• Vera Therapeutics' Interest Expenses stood at $599000.0 in 2022, then jumped by 76.29% to $1.1 million in 2023, then surged by 77.18% to $1.9 million in 2024, then rose by 1.76% to $1.9 million in 2025, then decreased by 4.25% to $1.8 million in 2026.
• The last three Interest Expenses figures came in at $1.8 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.